Ciprofloxacin/celecoxib or PrimeC is a fixed-dose combination of ciprofloxacin and celecoxib developed for ALS.[1][2]
| Combination of | |
|---|---|
| Ciprofloxacin | Fluoroquinolone antibiotic |
| Celecoxib | Cyclooxygenase-2 inhibitor |
| Clinical data | |
| Trade names | PrimeC |
| Legal status | |
| Legal status |
|
References
edit- ^ Priyan, Vishnu (6 December 2023). "NeuroSense's trial of ALS drug meets primary and secondary endpoints". Clinical Trials Arena. Retrieved 7 December 2023.
- ^ Salomon-Zimri, Shiran; Pushett, Avital; Russek-Blum, Niva; Van Eijk, Ruben P. A.; Birman, Nurit; Abramovich, Beatrice; Eitan, Erez; Elgrart, Katya; Beaulieu, Danielle; Ennist, David L.; Berry, James D.; Paganoni, Sabrina; Shefner, Jeremy M.; Drory, Vivian E. (3 April 2023). "Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS". Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 24 (3–4): 263–271. doi:10.1080/21678421.2022.2119868. PMID 36106817.